Vanderbilt University's campus design, placing research labs, a hospital, and computational cores in close proximity, created a unique "bench to bedside" environment. This physical integration of disciplines was a key catalyst for Wyatt McDonnell's career in computational biology and shaped his interdisciplinary approach to science.
10x Genomics' leadership was highly disciplined, intentionally avoiding therapeutics to focus on life science tools. This strategic focus created a clear market gap that employees like Wyatt McDonnell could see. It presented an opportunity to leave, found Infinimmune, and become a customer of 10x to pursue that untapped potential.
Infinimmune’s platform bypasses traditional discovery methods by reading antibodies directly from human memory B cells. The core insight is that the immune system has already spent a lifetime selecting and validating the most effective antibodies, providing a superior, de-risked starting point for new human therapeutics.
McDonnell describes the humbling experience of moving from academia to 10x Genomics and realizing his skills were subpar compared to industry veterans. He argues this process of discovering what you don't know is essential for becoming a better scientist and operating effectively under the uncertainty inherent in biotech.
Before single-cell sequencing became mainstream, Wyatt McDonnell saw a growing line of researchers for the 10x Genomics Chromium controller while other machines sat idle. This on-the-ground usage data acted as a powerful, leading indicator of a major technological disruption, predating broader industry and funding mandates.
At 10x Genomics, McDonnell learned that to gain buy-in from smart, 'finicky' scientists, one must avoid a critical posture. The most effective approach is framing ideas collaboratively, asking, 'Hey, I have an idea. What do you think?' This fosters consent and encourages meaningful contributions rather than defensive reactions.
Infinimmune's hiring process prioritizes 'judgment under uncertainty' by actively screening for people who are comfortable admitting the limits of their expertise. Wyatt McDonnell believes a team member who is confidently wrong is far more destructive to a high-stakes project than one who can honestly identify their knowledge gaps.
Infinimmune selected KBI Biopharma as its manufacturing partner partly because KBI's Celexis cell line is highly portable. This foresight de-risks future global scale-up, ensuring the manufacturing process can be easily transferred to different facilities worldwide, a key consideration for long-term commercialization and partnerships.
The 15-month process to sign the Merck partnership wasn't just about pitching Infinimmune's platform. A crucial element was showing continuous, tangible progress on Infinimmune's internal drug candidates. Proving they could create a real, manufacturable molecule gave Merck the conviction needed to sign the multi-million dollar deal.